openPR Logo
Press release

FDA Device Chief Calls for Stricter Regulation of Vaginal Mesh, Other Medical Devices

03-06-2012 07:15 AM CET | Politics, Law & Society

Press release from: Nadrich & Cohen LLP

Nadrich & Cohen, LLP reports that the FDA’s chief device regulator is calling for stricter governance of vaginal mesh and other medical devices.

Los Angeles, CA, March 2, 2012 – Nadrich & Cohen, LLP reports that the U.S. Food and Drug Administration’s top medical device regulator says the federal health agency needs more power to block the approval of unsafe medical devices.

According to a recent Bloomberg report, Jeffrey Shuren, director of the FDA’s Center for Devices and Radiological Health, says that the agency’s current regulatory policies have created a loophole that has allowed unsafe devices to reach the market, including vaginal mesh implants and faulty metal hip replacements. A number of House Democrats introduced a bill earlier this month which would provide for more government oversight of the medical device approval process. Legislators have also appealed to key Republicans to hold congressional hearings on the safety of vaginal mesh.

Legislators are specifically concerned over the FDA’s current 510(k) approval system, which allows medical device manufacturers to seek approval for a product without conducting additional safety testing. Under the 510(k) system, a company only has to demonstrate that their product is substantially similar to an existing product already on the market. It was under this system that Johnson & Johnson was able to gain approval for its Ethicon vaginal mesh implants, which were modeled on a mesh product developed by Boston Scientific Corp. That mesh device has since been recalled from the market.

Vaginal mesh was first approved to treat stress urinary incontinence related to pelvic organ prolapse in 1996. Since 2008, the FDA has received numerous adverse event reports from consumers who say they were injured by a vaginal mesh device. The implants have been linked to a wide range of side effects, including pain, infection, scarring, tissue damage, bladder and bowel perforation, recurrence of pelvic organ prolapse and painful intercourse. In July 2011, the FDA issued an updated safety communication advising patients and health care professionals that the risks associated with transvaginal mesh may outweigh its benefits.

A number of women have subsequently filed suit against several high-profile manufacturers of vaginal mesh devices, including Johnson & Johnson, C.R. Bard and Boston Scientific. The plaintiffs claim that the companies were aware of the potential risk to women who used the mesh devices but did not adequately warn consumers of the dangers.

Women who suffered complications after being implanted with vaginal mesh are urged to seek the advice of an experienced personal injury lawyer to protect their rights. The vaginal mesh attorneys at Nadrich & Cohen, LLP are now offering confidential, no-cost consultations to women in all 50 states who believe they were harmed by one of these devices. Help is available by calling the firm’s injury hotline at 1-800-722-0765 or by completing an online case evaluation form at www.vaginalmeshlegalclaims.com.

Nadrich & Cohen LLP is a national law firm with offices in Los Angeles, Sacramento, San Diego and other cities throughout California. The firm specializes in handling mass tort actions and representing individuals in cases involving pharmaceutical companies, medical device makers and other product manufacturers. The firm is committed to achieving the best outcome possible in every case and has recovered over $200 million in settlements on behalf of its clients.

In addition to handling vaginal mesh side effects claims, Nadrich & Cohen, LLP is also investigating cases involving Yaz, Actos, DePuy Hip Implants, Zimmer Hips, Wright Conserve Hips, Pradaxa, Reflex Sympathy Dystrophy, Fen Phen and PPH, Depakote and Reglan. All cases are accepted on a contingency basis, meaning there is never a fee unless a judgment is recovered on your behalf.

Jennifer Poole
National Client Intake Coordinator
Nadrich & Cohen LLP
12100 Wilshire Blvd.
Suite 1250
Los Angeles, CA 90025
800-718-4658
info@personalinjurylawcal.com
www.personalinjurylawcal.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release FDA Device Chief Calls for Stricter Regulation of Vaginal Mesh, Other Medical Devices here

News-ID: 213019 • Views:

More Releases from Nadrich & Cohen LLP

Yaz Lawsuit Settlements Reach $142 Million
Nadrich & Cohen, LLP reports that Bayer is continuing to offer settlements to plaintiffs involved in federal Yaz side effects litigation. Los Angeles, CA, April 27, 2012 – Nadrich & Cohen, LLP reports that German drug-maker Bayer AG has settled approximately 651 Yaz side effects lawsuits totaling $142 million. Earlier this month, it was reported that the drug-maker had reached settlements in approximately 500 cases filed by women who claimed
Yaz, Yasmin to Get New Labels as FDA Warns of Blood Clot Risk
Nadrich & Cohen, LLP reports that Yaz and similar birth control pills are to receive updated warning labels advising patients of the risk for developing serious blood clots. Los Angeles, CA, April 10, 2012 – National law firm Nadrich & Cohen, LLP has learned that the U.S. Food and Drug Administration has ordered Bayer to produce new warning labels for several of its oral contraceptives, including Yaz, Yasmin and Beyaz.
FDA Schedules Advisory Panel Meeting to Discuss Metal Hip Safety
Nadrich & Cohen, LLP reports that the FDA has scheduled an advisory panel to discuss the safety of metal hip implants. Los Angeles, CA, March 29, 2012 – National law firm Nadrich & Cohen, LLP has learned that the U.S. Food and Drug Administration has a scheduled an advisory panel meeting to discuss the safety of metal hip implants and all-metal hip resurfacing systems. The two-day panel, which is expected
Pradaxa Side Effects Lawsuits Filed in Federal Court
Nadrich & Cohen, LLP reports that three Pradaxa side effects lawsuits have been filed in federal courts across the country. Los Angeles, CA, March 7, 2012 – National law firm Nadrich & Cohen, LLP has learned that three Pradaxa side effects lawsuits have been filed against Boehringer Ingelheim, the drug’s manufacturer. The cases were filed in federal district courts located in Tennessee, Kentucky and Louisiana and it’s believed they are the

All 5 Releases


More Releases for FDA

Exosomes Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances, Latest FDA …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Exosomes pipeline constitutes 70+ key companies continuously working towards developing 75+ Exosomes treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Exosomes Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Exosomes Market. The Exosomes Pipeline report embraces in-depth commercial and clinical
Dengue Pipeline Drugs, FDA Approvals, and Companies 2024
DelveInsight's, "Dengue- Pipeline Insight 2024" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Dengue pipeline landscape. It covers the Dengue pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in Dengue Research. Learn more about our innovative
DreaMed receives 5th FDA Clearance
TEL AVIV, Israel: DreaMed Diabetes LTD. ("DreaMed" or the "Company"), developer of the endo.digital Clinical Decision Support System announced today that it has received its 5th U.S Food and Drug Administration (FDA) clearance that expands the scope of AI enhanced treatment recommendations to patients on fixed meal insulin regimens. endo.digital is the first decision support system that has been cleared to assist healthcare providers in the management of diabetes
Fully Differential Amplifier (FDA) Market Shows Strong Expansion |
The most recent report published by Market Research Inc. indicates that the Fully Differential Amplifier (FDA) Market is likely to accelerate significantly in the next few years. Specialists have studied market drivers, restraints, risks and prospects in the global market. The Fully Differential Amplifier (FDA) Market report shows the likely direction of the market in the coming years along with its assessments. By analyzing the competitive landscape, the authors of
St. Louis-based Air Cleaner Earns FDA Clearance
Micron Pure develops tech powering CerroZone, a Berkshire Hathaway and Marmon Holdings Company. Chesterfield, Missouri, July 21, 2022. Micron Pure is pleased to announce that its patented ozone technology recently received Federal Drug Administration (FDA) 510(k) Class II clearance for the CerroZone Mobile device as a recirculating air cleaner for eliminating airborne Viruses and Bacteria. Micron Pure has licensed the technology to Marmon Holdings, a Berkshire Hathaway Company, who will be selling Air
FDA SETS A NEW GOAL FOR SODIUM REDUCTION
The U.S. Food and Drug Administration released voluntary short-term (2,5 year) sodium reduction guidelines for the food industry on October 14, 2021. The new guidelines include sodium reduction targets for 163 categories of commercially processed, packaged, and restaurant foods. The FDA aims to address the excessive intake of sodium among Americans and promote better public health. The new sodium reduction guidelines will affect food manufacturers, chain restaurants, and foodservice operators. According